Moderna, Inc.

Overview

Moderna is the rare platform-biotech company whose defining product was built as a public–private partnership: its mRNA-1273 COVID-19 vaccine was, in the words of the US health secretary at the time, “developed by Moderna in partnership with the NIH,” with the Biomedical Advanced Research and Development Authority reimbursing 100% of allowable development costs under a $955 million contract (Contract Pharma). A decade earlier the company had been a secretive startup — its incoming chief executive joined a business with a single staff scientist and one mouse experiment behind it (Boston Magazine). The vaccine received FDA emergency authorization in December 2020 and full approval as Spikevax in January 2022 (Reuters). Moderna’s second act is now a personalized melanoma therapy: on August 19, 2026, Moderna and Merck announced that the Phase 3 INTerpath-001 trial of intismeran autogene met its primary and key secondary endpoints — but detailed data are unpublished and the therapy is investigational, not approved (Medscape).

What the organization is known for

Moderna is known for treating messenger RNA as a programmable platform rather than a one-drug discovery. Synthetic mRNA — a short transcript of a longer DNA code — instructs cells to produce copies of a chosen protein without affecting the body’s own genetic code; for COVID-19 that protein was the “spike” seen on the surface of the coronavirus, against which the body produces neutralizing antibodies (pharmaphorum). The platform’s promise, pitched from the company’s earliest days, was speed: once the genetic sequence of a target was known, a new vaccine could be designed within days, with the rigorous clinical trials taking the months (pharmaphorum).

The company is equally known for how it spent its first decade: operating in stealth mode after its September 2010 founding, raising more than $2.6 billion in private funding rounds while guarding details of its technology, and going public in December 2018 in what was then the largest biotech IPO in history — raising $500 million under the ticker MRNA (pharmaphorum). It had no commercial products until the pandemic.

Products and services

Moderna’s first commercial product was its COVID-19 vaccine, mRNA-1273. The FDA issued emergency use authorization on December 18, 2020, and granted full approval on January 31, 2022, for people aged 18 and older under the brand name Spikevax — making it the second fully approved COVID-19 vaccine in the United States, after the Pfizer/BioNTech shot (Reuters). Updated formulations tracking circulating variants have been approved in subsequent years, most recently the 2026–2027 formulas in August 2026 (Drugs.com).

Its second approved product was mRESVIA (mRNA-1345), an RSV vaccine approved on May 31, 2024, for adults aged 60 and older — the first time an mRNA vaccine was approved for a disease other than COVID-19 (Drugs.com). The approval rested on the Phase 3 ConquerRSV trial in approximately 37,000 older adults across 22 countries, which found 83.7% efficacy against RSV lower respiratory tract disease in the primary analysis, published in the New England Journal of Medicine (Drugs.com).

A third product followed: mNEXSPIKE (mRNA-1283), a next-generation COVID-19 vaccine first approved in May 2025, after a Phase 3 trial in approximately 11,400 participants showed it was non-inferior to Spikevax, with 9.3% higher relative vaccine efficacy (Drugs.com). The investigational pipeline’s most watched program is intismeran autogene, a personalized melanoma therapy developed with Merck — each dose individually designed from mutations in the patient’s own tumor and administered with pembrolizumab (Medscape).

Ownership, founders and leadership

Moderna was founded in September 2010 in Massachusetts as ModeRNA Therapeutics, emerging from stem-cell biologist Derrick Rossi’s published work on modified mRNA and incubated by Flagship VentureLabs under Noubar Afeyan (Boston Magazine). Rossi was joined by physician-researcher Kenneth Chien and MIT professor Robert Langer, with Harvard’s Tim Springer as an initial investor and board member (Boston Magazine). The company’s name derives from “modified RNA” — also read as “modern” (pharmaphorum).

Stéphane Bancel has been chief executive since early 2011, when he left a senior post at the French diagnostics company bioMérieux — then doing $2 billion in annual sales — to join the startup (Boston Magazine). The company is publicly traded on Nasdaq under MRNA following its 2018 IPO (pharmaphorum).

Funding and acquisitions

Before any product revenue, Moderna raised more than $2.6 billion in private funding rounds (pharmaphorum). Its pivotal funding came from the US government: in addition to the $955 million BARDA development award, a U.S. Department of Defense contract worth up to $1.525 billion secured 100 million doses of mRNA-1273, with an option to purchase 400 million more — bringing total US commitments to up to $2.48 billion, all under Operation Warp Speed (Contract Pharma).

The company’s first-ever acquisition came in January 2023: Japanese firm OriCiro Genomics K.K. for US$85 million, gaining cell-free DNA synthesis and amplification technology — described by Bancel as a key building block in mRNA manufacturing — along with its roughly 20–30 employees in Tokyo (The Straits Times).

Regulation, licenses and compliance record

Moderna’s COVID-19 vaccine received FDA emergency use authorization on December 18, 2020, and full FDA approval (a biologics license) on January 31, 2022, for adults 18 and older (Reuters; Drugs.com). Regulators have attached post-marketing warnings to authorized mRNA COVID vaccines: increased risks of myocarditis and pericarditis, with onset typically in the first week after vaccination and the observed risk highest in males 12 through 24 years of age (Drugs.com). Reuters reporting at the time of approval noted that both the Moderna and Pfizer/BioNTech vaccines had been linked to rare cases of heart inflammation called myocarditis, particularly among young men, with some studies suggesting the risk was higher with Moderna’s shot (Reuters).

Timeline

• 2010 — Founded in September in Massachusetts as ModeRNA Therapeutics, from Derrick Rossi’s modified-mRNA work, incubated by Flagship VentureLabs under Noubar Afeyan (Boston Magazine; pharmaphorum).
• 2011 — Stéphane Bancel joins as chief executive from bioMérieux (Boston Magazine).
• 2018 — Goes public in the then-largest biotech IPO in history, raising $500 million (ticker MRNA) (pharmaphorum).
• 2020 — US government commits $955 million in development funding (BARDA) and up to $1.525 billion in supply contracts (DoD) for mRNA-1273; Phase 3 COVE study runs with NIAID and BARDA (Contract Pharma); FDA emergency use authorization follows on December 18 (Drugs.com).
• 2022 — Full FDA approval of Spikevax on January 31, for ages 18+ (Reuters).
• 2023 — First-ever acquisition: OriCiro Genomics K.K. for US$85 million (The Straits Times).
• 2024 — FDA approves mRESVIA (RSV, adults 60+) on May 31 — the first mRNA vaccine approved for a non-COVID disease (Drugs.com).
• 2025 — mNEXSPIKE (mRNA-1283) receives its first FDA approval in May (Drugs.com).
• 2026 — INTerpath-001 Phase 3 success announced August 19: intismeran autogene plus pembrolizumab prolongs recurrence-free survival versus pembrolizumab alone in resected high-risk melanoma (Medscape).

Competitors and partners

Moderna’s most consequential partner was the US government: BARDA funded development, the Department of Defense contracted supply, and the NIH’s NIAID collaborated on the Phase 3 COVE study and the vaccine’s early development (Contract Pharma). It also partnered with AstraZeneca on cardiovascular, metabolic, renal and cancer programs (pharmaphorum), and with Merck on the intismeran autogene personalized cancer program (Medscape). Its defining competitor in mRNA vaccines was the Pfizer/BioNTech partnership, whose shot received full FDA approval first (Reuters).

What this profile does not claim

This profile does not claim Spikevax’s peak or lifetime revenue, which were not verified from SEC filings or tier1 reporting in a fully-read source. It does not claim that intismeran autogene extends survival or is safe and effective: only topline Phase 3 results have been announced, detailed efficacy and safety data had not been published as of the profile date, and the therapy is investigational, not approved. It does not describe Moderna’s patent disputes or its 2023 NIH/Dartmouth/Scripps settlement, which were not verified in fully-read sources. The characterization of the COVID vaccine as “developed by Moderna in partnership with the NIH” is the US health secretary’s contemporaneous description; the profile does not apportion invention credit beyond that.